A growing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis , the most prevalent form of MS. Nevertheless, all approved drugs have clinical shortcomings in terms of efficacy, safety, tolerability, and/or delivery, creating opportunities for new and improved DMTs, be they incremental or pioneering. This content provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals in the management of relapsing MS and the current level of unmet need in this area. We analyze the commercial opportunities and how new / emerging novel and next-generation compounds may capitalize on these opportunities.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for relapsing forms of MS?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals?
  • What are the prevailing areas of unmet need and opportunity in relapsing MS?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new drug for relapsing MS?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Multiple Sclerosis - Unmet Need - Detailed, Expanded Analysis - Relapsing Forms Of MS (US/EU)
    • Executive Summary
      • Unmet Need - Relapsing Forms of MS - Executive Summary - June 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Rationale for Drug Selection
          • Products for Relapsing Forms of MS and Rationale for Drug Selection
      • Treatment Drivers and Goals
        • Key Findings: Attribute Importance
        • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Neurologists' Prescribing Decisions in Relapsing Forms of MS
        • Importance of Efficacy Attributes to Prescribing Decisions in Relapsing Forms of MS: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Relapsing Forms of MS: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Relapsing Forms of MS: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Relapsing Forms of MS: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Relapsing Forms of MS: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Relapsing Forms of MS: Europe
        • Importance of Nonclinical Factors to Prescribing Decisions in Relapsing Forms of MS: United States
        • Importance of Nonclinical Factors to Prescribing Decisions in Relapsing Forms of MS: Europe
        • Key Findings: Stated vs. Derived Importance
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Relapsing Forms of MS: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Relapsing Forms of MS: Europe
      • Product Performance Against Treatment Drivers and Goals
        • Key Findings
        • Overall Performance of Key Therapies for Relapsing Forms of MS: United States
        • Overall Performance of Key Therapies for Relapsing Forms of MS: Europe
        • Mean Overall Performance of Key Therapies for Relapsing Forms of MS: United States and Europe
        • Relative Performance of Key Therapies for Relapsing Forms of MS Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for Relapsing Forms of MS Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for Relapsing Forms of MS Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for Relapsing Forms of MS Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for Relapsing Forms of MS Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for Relapsing Forms of MS Across Select Convenience of Administration Attributes: Europe
        • Relative Performance of Key Therapies for Relapsing Forms of MS Across Select Nonclinical Attributes: United States
        • Relative Performance of Key Therapies for Relapsing Forms of MS Across Select Nonclinical Attributes: Europe
      • Assessment of Unmet Need
        • Key Findings: Unmet Need in Relapsing Forms of MS
        • Surveyed Neurologists’ Satisfaction with the Performance of Key Therapies for Relapsing Forms of MS on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Neurologists’ Satisfaction with the Performance of Key Therapies for Relapsing Forms of MS on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Relapsing Forms of MS: United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Relapsing Forms of MS: Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Relapsing Forms of MS: United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Relapsing Forms of MS: Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Relapsing Forms of MS: United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Relapsing Forms of MS: Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Relapsing Forms of MS: United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Relapsing Forms of MS: Europe
        • Key Findings: Unmet Need in Relapsing Forms of MS and Related Indications
        • Surveyed Neurologists' Ascribed Level of Unmet Need in Relapsing Forms of MS and Related Indications: United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need in Relapsing Forms of MS and Related Indications: Europe
      • Opportunity Analysis
        • Areas of Opportunity in the Relapsing Forms of MS Market and Emerging Therapy Insights
          • Opportunity: More Effective DMTs, Especially on Disability Progression
          • Opportunity: DMTs That Are Safer and/or Better Tolerated Than Current Options
          • Opportunity: Enhanced Convenience of Administration
      • Target Product Profiles
        • Assessing Drug Development Opportunities
        • Target Product Profile Methodology
          • Attributes and Attribute Levels
          • Attributes of Key Current and Late-Phase Emerging Therapies for Relapsing Forms of MS
        • Attribute Importance and Part-Worth Utilities
          • Relapsing Forms of MS Target Product Profile: Attribute Importance
          • Reduction in ARR vs. Active Comparator over Two Years
          • Reduction in Risk of Three-Month SDP vs. Active Comparator over Two Years
          • Incidence of GI-Related Side Effects (not placebo-adjusted)
          • Overall Risk of PML
          • Monitoring Requirements
          • Price per Day
        • Conjoint Analysis-Based Simulation of a Market Scenario
          • Relapsing Forms of MS Market Simulation: Share of Preference of Target Product Profiles Included in Market Scenario 1
          • Relapsing Forms of MS Market Simulation: Likelihood to Prescribe Target Product Profiles Included in Market Scenario 1
          • Relapsing Forms of MS Market Simulation: Target Product Profiles Included in Market Scenario 1
          • Relapsing Forms of MS Market Simulation: Share of Preference of Target Product Profiles Included in Market Scenario 2
          • Relapsing Forms of MS Market Simulation: Likelihood to Prescribe Target Product Profiles Included in Market Scenario 2
          • Relapsing Forms of MS Market Simulation: Target Product Profiles Included in Market Scenario 2
      • Appendix
        • Key Abbreviations
        • Bibliography

    Author(s): Niyati Khetarpal, Ph.D

    "Niyati Khetarpal is a business insights analyst on the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group. In this role, she conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including epilepsy and MS. She also has specific expertise in patent/IP research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope proteins.”


    Related Reports

    Multiple Sclerosis - Current Treatment - Treatment Algorithms - Claims Data Analysis: Multiple Sclerosis - Refreshed Dashboard 2021 (US)

    With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

    View Details

    Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

    The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

    View Details

    Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

    The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

    View Details

    Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

    Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

    View Details